Skip to main content
AMP 2025 Annual Meeting & Expo Main banner
Final Program


    Molecular Residual Disease (MRD): The Current Landscape, Key Challenges, and Future Opportunities

    Wednesday, November 12, 2025
    11:00 AM - 11:50 AM EST
    Location: 160B, Level 1

      Corporate Workshop Speaker(s)

    • IS

      Ian Silverman

      Associate Director, Biopharma Business Development
      Foundation Medicine

      • Corporate Workshop Panelist(s)

    • HT

      Hanna Tukachinsky

      Clinical Development Associate Director
      Foundation Medicine

    • ES

      Erica Schleifman

      Senior Director, Cancer Biomarker Development
      AstraZeneca

    • AP

      Aparna R. Parikh, MD

      Associate Professor, Medicine
      Harvard Medical School

    Join Foundation Medicine and key industry experts for a presentation and panel discussion on molecular residual disease (MRD). MRD has the potential to transform drug development and treatment in early and late-stage cancers. This session will highlight MRD’s implications for clinical trial enrollment, treatment response monitoring (TRM), and clinical decision-making, as well as introduce Foundation Medicine’s tissue-informed MRD assay.

    The panel will bring together biopharmaceutical, clinical, and diagnostic industry leaders for a discussion on the utility of MRD for the biopharmaceutical field. It will address the following topics:
    • Current and future landscape for the solid tumor MRD field
    • Considerations when deciding on an MRD solution
    • What is needed to move the field toward clinical adoption